Myokine Identification Following Acute Exercise

March 6, 2025 updated by: Rockefeller University

Identification of Exercise-induced Myokines Regulating the Muscle-adipose Signaling Axis

Exercise stimulates a cascade of responses within the human body. For example, exercise results in the release of proteins into the circulation which communicate with cells and organs throughout the body. In fact, recent human research identified more than 600 proteins are released into the blood circulation following short-term exercise, many of which are predicted to come from the skeletal muscle and target the fat tissue. However, identification of these muscle-secreted proteins and their target tissue (i.e. fat tissue) remains extremely challenging. This challenge is because tissue needs to be collected from multiple sites (skeletal muscle and fat) and at multiple timepoints (before and after exercise). This study seeks to address these challenges through the collection of fat and blood both before and after short-term exercise followed by protein detection (of the blood) and gene expression (of the fat tissue).

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Acute exercise stimulates a cascade of responses within the human body. Not only do tissues work in an autonomous manner, but they also secrete factors mediating interorgan communication. Recent human research identified >600 proteins secreted into the circulation following an acute bout of exercise, many of which are predicted to derive from the skeletal muscle and target the adipose tissue. Indeed, human studies have validated the effect exercise-induced myokines have upon adipose physiology, most notably IL-6. While insightful, identification of myokines and their tissue of target (i.e. adipose tissue) remains extremely challenging in humans. This is largely due to the need for tissue collection from multiple sites (skeletal muscle and adipose tissue) and at multiple timepoints (before and after exercise). To address these challenges, This study will implement an acute bout of exercise in a human cohort, followed by tissue collection and in-depth secretome and tissue protein analysis. This study will accomplish these goals through tissue and blood collection at multiple timepoints before and after exercise followed by in-depth proteome and transcriptome analysis.

For the first in-person visit, participants will arrive to The Rockefeller University Hospital between 8:00am to 10:00am in a non-fasted state. All participants will be asked to keep track of their food consumption both the night prior to and the day of the visit. Participants will be asked to consume their breakfast 2-hours prior to arrival, and will be asked to eat their habitual breakfast. Participants will be asked to refrain from intense physical activity 48 hours prior to the testing day, any caffeinated beverages the day of arrival, and any alcoholic beverages for 24-hours prior to arrival.

Height, weight, resting heart rate, blood pressure, and body composition, will be measured. Blood will be collected from the upper arm for blood chemistry analyses including HbA1c (%), Cholesterol (mg/dl), LDL-cholesterol (mg/dl), HDL-cholesterol (mg/dl), Triglyceride (mg/dl), Complete blood count (CBC), and High sensitivity C-reactive protein (hsCRP). An additional 20mL of blood will be drawn from the arm for protein identification through the use of proteomics. Subcutaneous adipose from the lower abdomen will be collected following blood collection.

Following a minimum of one week from fat sample collection, participants will take part in a maximal aerobic consumption (VO2max) test between 8:00am-10:00am. Participants will arrive in a non-fasted state, but all participants will be asked to keep track of their food consumption the night prior to, and the morning of, the VO2max test. When possible, the investigators will recommend the participants to consume the identical dinner/breakfast to that consumed prior to the first in-person visit. Participants will be asked to consume their breakfast 2-hours prior to arrival. Additionally, participants will be asked to refrain from intense physical activity 48 hours prior to the testing day, any caffeinated beverages the day of arrival, and any alcoholic beverages for 24-hours prior to arrival.

For VO2max testing, participants will take part in a general warm up consisting of walking on a motorized treadmill for 5 minutes followed by performing a graded exercise test (GXT) on a motorized treadmill while wearing a one-way, non-rebreathing Hans Rudolph 7450 series V2 mask that allows for the evaluation of all expired air which is calibrated prior to each test. Volume of ventilated expired air as well as oxygen and carbon dioxide concentrations of expired air will be determined using a commercial metabolic cart (Parvo Medics' TrueOne® 2400, Parvo, UT). Specifically, the investigators will incorporate the Ellestad Protocol to determine the participants VO2max. The Ellestad Protocol is divided into 8 phases which gradually increases in speed and incline throughout the test. To confirm that the VO2max test is eliciting a metabolic response, lactate measurements through the use of a finger prick will be taken both before and immediately following the exercise test. Additionally, participants will wear a light-weight heart rate monitoring device (Polar) strapped around the upper torso during testing to track heart rate throughout exercise.

The VO2max test will continue until the participant reaches volitional fatigue defined by reaching a rate of perceived exertion (RPE) greater than 19 (using the Borg RPE Scale), OR a respiratory exchange ratio (RER) reaching above 1.1, OR a participant choosing to cease exercise for any reason.

Blood will be collected from the arm immediately following exercise, 1-hour following the exercise, and 3-hours following exercise. Adipose will be collected Immediately following the final blood draw, participants will be prepped for adipose tissue collection (from the abdominal subcutaneous adipose). This will occur 3-hours following exercise.

Study Type

Interventional

Enrollment (Actual)

12

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • New York
      • New York, New York, United States, 10065
        • Rockefeller University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • passing the PARQ questionnaire (i.e. answering "NO" to all questions)
  • being between the ages of 18-45
  • being moderately active (defined as participating in 30 minutes of recreational activity at least once per week for the past 3 months but no more than 3 times per week)
  • non-smoking
  • free of metabolic or cardiovascular diseases

Exclusion Criteria:

  • unhealed fractures
  • thrombophlebitis (blood clots)
  • recent surgery of the upper or lower extremities (any surgeries in past 6 months at the ankle or foot, or in the past year at the knee, hip, shoulder or elbow)
  • recent uncontrolled bruising
  • recent muscle, bone or joint damage which interferes with regular physical activity
  • taking part in vigorous physical activity more than 3 times per week
  • any prior sensations of chest pain during exercise.
  • individuals who are pregnant as determined by an on-site pregnancy test
  • individuals who are currently taking exogenous hormones
  • individuals who chronically consume NSAIDS or other anti-inflammatory medication (every day for the previous 3 months)
  • failing the PARQ questionnaire as indicated by answering "YES" to any of the questions
  • Having a BMI >32
  • Any medical condition that in the opinion of the investigator will confound interpretation of data for analysis.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Secretome characterization and signaling to the adipose tissue
To identify possible exercise stimulated secreted proteins which signal to the adipose tissue, subcutaneous adipose and blood will be collected both before and at multiple timepoints following a VO2max test. Adipose will be collected from the abdominal subcutaneous region and blood will be collected from the arm. Blood will be analyzed for change in protein abundance and adipose will be analyzed for change in gene expression.
Participants will take part in a VO2max test. This will include a graded exercise test (GXT) on a motorized treadmill while wearing a one-way, non-rebreathing valve and nose clip that allows for the evaluation of all expired air. Specifically, we will incorporate the Ellestad Protocol. The Ellestad Protocol is divided into 8 phases which gradually increases in speed and incline throughout the test. The VO2max test will continue until the participant reaches volitional fatigue defined by reaching a rate of perceived exertion (RPE) greater than 19 (using the Borg RPE Scale), OR a respiratory exchange ratio (RER) reaching above 1.1, OR a participant choosing to cease exercise for any reason.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Identification and quantification of exercise-induced proteins released into the blood through the use of proteomic analysis.
Time Frame: Before exercise, immediately following exercise, 1-hour following exercise, 3-hours following exercise
The change in protein abundance within the circulation will be identified by using proteomic-based detection methods. Proteins detected from the control timepoint (before exercise), will be compared to the three timepoints following exercise.
Before exercise, immediately following exercise, 1-hour following exercise, 3-hours following exercise

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Characterize changes in gene expression of the subcutaneous adipose tissue following exercise through the use of bulk RNA-sequencing.
Time Frame: 1 week pre-intervention, 1-hour following, 3-hours following
Bulk RNA-sequencing of subcutaneous adipose tissue will be analyzed both before and following acute exercise. The investigators will seek to identify those genes which show differential gene expression between the pre and post exercise timepoints.
1 week pre-intervention, 1-hour following, 3-hours following

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Luke Olsen, PhD, The Rockefeller University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 18, 2024

Primary Completion (Actual)

August 9, 2024

Study Completion (Actual)

August 9, 2024

Study Registration Dates

First Submitted

November 30, 2023

First Submitted That Met QC Criteria

January 15, 2024

First Posted (Actual)

January 25, 2024

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

March 6, 2025

Last Verified

March 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • LOL-1044

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Adiposity

Clinical Trials on Exercise

Subscribe